Cell-free Therapy
EV for tissue regeneration
Phase I: MSC-EV treating liver cirrhosis
PI: Dr. Hoang Thanh Van Co-PIs: Prof. Nguyen Thanh Liem and Dr. Nguyen Ngoc Quang
Evaluation of the Safety of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Treating Liver Fibrosis: Phase I Clinical Trial
1) Main objectives:
Evaluate the safety of umbilical cord mesenchymal stem cell secretions (VinEV-3) in cirrhosis patients at designed doses
Determine the recommended dose of VinEV-3 for phase 2 clinical trials
2) Secondary objectives:
Evaluate changes in serum ALB, AST, ALT, GGT, ALP levels, Child-Pugh score, MELD score, and quality of life after VinEV-3 treatment
Part 1 preclinical: Safety of MSC-EV testing on monkeys
Prof. Nguyen Thanh Liem
Evaluation of the safety of mesenchymal stem cell-derived extracellular vesicles on monkeys (Phase 1)
Evaluate the safety of MSC-EV sourcing from AD-MSC and UC-MSC at different doses up to 100 billion EV/kg
Part 2/3 preclinical: Safety of intensive doses of MSC-EV testing on monkeys
Prof. Nguyen Thanh Liem
Evaluate the safety of VinEV over 9 months with repeat intensive injection of 1X (100 billioin EV/kg), 2X and 3X doses.
Initially investigate the anti-aging effects of VinEV in genetic stability, aging-gen reduction and balancing cell metabolism
EV for antiaging
VinVital as a dietary supplement to improve the health of the elderly
Prof Nguyen Thanh Liem & Dr. Nguyen Thi Quyen
Evaluation of the safety and efficacy of VinVital, a dietary supplement containing adipose mesenchymal stem cell secretomes, to improve the health of the elderly
1. Production of VinVital, a dietary supplement containing secretoms from AD-MSCs
2. Evaluation of safety and efficacy of VinVital in improving elderly healthy